贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效

目的：比较贝伐珠单抗联合顺铂与单药顺铂两组方案治疗肺癌恶性胸水的安全性和有效性。方法：选取2014 年11月至2017 年11 月葫芦岛市医院肿瘤内科27 例确诊为肺癌恶性胸水的患者，其中14 例采用贝伐珠单抗联合顺铂治疗方案、13 例采用顺铂方案,比较两组临床疗效及不良反应。结果：治疗前两组患者的一般情况比较，差异无统计学意义（P>0.05）；贝伐珠单抗联合顺铂组患者的近期疗效优于顺铂组（92.9% vs 61.5%，P<0.05）。治疗过程中不良反应主要为骨髓抑制和消化道不适反应等，两组患者不良反应发生率相近，差异均无统计学意义（P>0.05）。结论：与单药顺铂方案相比，应用贝伐珠单抗联合顺铂方案治疗肺癌恶性胸水患者具有更好的近期疗效，两种方案的不良反应相当。

Clinical efficacy of bevacizumab combined with cisplatin regimen in the treatment of malignant pleural effusion in lung cancer patients

Objective: To compare the safety and efficacy of bevacizumab plus cisplatin and cisplatin alone in the treatment of malignant pleural effusion of lung cancer patients. Methods: From November 2014 to November 2017, 27 patients diagnosed with lung cancer complicated with malignant pleural effusion at the department of Oncology, the Central Hospital of Huludao, were enrolled in this study. Fourteen patients received bevacizumab plus cisplatin and thirteen patients received cisplatin alone. The clinical efficacy and adverse reactions were compared between the two groups. Results: There was no significant difference in the general condition between the two groups before treatment(P>0.05). The bevacizumab group had better short-term efficacy than the cisplatin group and the difference was statistically significant(92.9% vs 61.5%, P<0.05). The main adverse reactions during the treatment were bone marrow suppression and gastrointestinal discomfort, etc. The incidence of adverse reactions was similar between the two groups, with no statistically significant difference(P>0.05). Conclusion: Compared with cisplatin alone, bevacizumab combined with cisplatin has better shortterm efficacy in the treatment of lung cancer patients with malignant pleural effusion. The adverse reactions were quite similar.